US EditionGLP-1s: Acute pancreatitis warning added to product info
5 Articles
5 Articles
GLP-1s: Acute pancreatitis warning added to product info
The link between GLP-1 receptor agonists and acute pancreatitis has long been the topic of research. Now, UK regulators have ruled that this link should be added to product information. More than a thousand cases of the disease, and 19 deaths, have been linked to GLP-1s.
The symptoms to be observed include intense pain which does not occur in stomach and back.
The United Kingdom health regulatory agency has issued a warning of serious cases of severe pancreatitis in patients who use the so-called emigrative pens such as Mounjaro and Ozempic. It understands what is known about the relationship of the medicine with the disease. According to the institution’s communication, breast-feeding pens may cause some complications in pancreatitis and vesicles.
The United Kingdom Medicines and Products Regulatory Agency (MHRA) (like Anvisia in Brazil) warned about a rare risk of severe acute pancreatitis in patients who use GLP-1 and/or GIP analogues, category in which they are the trizepatid (active principle of Mounjaro) and semagglutide (presented in Ozempic and Wegovy). The acute pancreatitis is already known, but uncommonly, for the use of these medicines. In some very rare cases, acute pancreatit…
A warning published by Medicines and Healthcare products Regulatory Agency (MHRA), a governing body of drugs in the United Kingdom, re-examined the international debate on the safety of so-called medicines injectable to control weight and diabetes, popularly known as “emigrative channels”. The communication points to the existence of rare, but serious, pancreatitis associated with the use of drugs of the GLP-1 receptor class, such as Ozempic, We…
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
